Protiva Ends Suit Against Merck Unit After Merck Licenses Protiva's RNAi Technology | GenomeWeb
NEW YORK (GenomeWeb News) — Merck has licensed RNAi technology from Protiva Biotherapeutics, and Protiva has agreed to drop ongoing litigation against the drug maker’s subsidiary Sirna Therapeutics, Protiva said this week.
 
Merck will use Protiva’s stable nucleic acid-lipid particles, or SNALP, technology in its pharmaceutical-development programs, Protiva said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.